ConductScience.org, home

Comparison · NCT04550936-be7c599e

Invasive Aspergillosis vs Mucormycosis: All-Cause Mortality at Week 24

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Invasive Aspergillosis vs Mucormycosis: All-Cause Mortality at Week 24. Trial comparisons, record NCT04550936-be7c599e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04550936-be7c599e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.4630.3950.532wilson
Risk in group 20.2940.1330.531wilson
Risk difference, group 1 minus group 20.169-0.07810.344newcombe hybrid score
Risk ratio, group 1 over group 21.570.7423.33log
Odds ratio, group 1 over group 22.070.7026.08log
Number needed to treat, for one more participant with the outcome on Invasive Aspergillosis than on Mucormycosis5.93from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Invasive Aspergillosis
Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
93201OG000
Group 2Mucormycosis
Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
517OG001

Outcome

Type
PRIMARY
Title
All-Cause Mortality at Week 24
Description
Number of participants who died due to any cause at Week 24 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.
Time frame
Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Population
Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Source ClinicalTrials.gov

Trial

Title
A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
NCT number
NCT04550936
Phases
Conditions
Invasive Aspergillosis, Mucormycosis
Interventions
Isavuconazole
Lead sponsor
Pfizer
Results first posted
2025-12-09

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04550936-be7c599e